Sydney Lou Bonnick. Show Affiliations »
Abstract
Mesh: See more » Alendronate/administration & dosageAlendronate/therapeutic useBisphosphonate-Associated Osteonecrosis of the Jaw/epidemiologyBone Density Conservation Agents/administration & dosageBone Density Conservation Agents/adverse effectsBone Density Conservation Agents/therapeutic useDiphosphonates/administration & dosageDiphosphonates/adverse effectsDiphosphonates/therapeutic useEsophageal Neoplasms/chemically inducedEtidronic Acid/administration & dosageEtidronic Acid/analogs & derivativesEtidronic Acid/therapeutic useFemoral Fractures/chemically inducedHip Fractures/chemically inducedHumansImidazoles/administration & dosageImidazoles/therapeutic useKidney/drug effectsOsteoporosis, Postmenopausal/drug therapyOsteoporotic Fractures/prevention & controlRenal Insufficiency/chemically inducedRisedronic AcidRisk AssessmentZoledronic Acid
Substances: See more » Bone Density Conservation AgentsDiphosphonatesImidazolesZoledronic AcidRisedronic AcidEtidronic AcidAlendronate
Year: 2011 PMID: 22051091 DOI: 10.1016/j.jocd.2011.07.006
Source DB: PubMed Journal: J Clin Densitom ISSN: 1094-6950 Impact factor: 2.617